SCHEMBL4795024

SCHEMBL4795024

NC(Cc1cccc(C(F)(F)F)c1)C(=O)N1CCN(C(=O)c2cc(F)ccc2F)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.76
MDM2 Q00987 1/20 0.52
DPP4 P27487 4/20 0.50
DPP7 Q9UHL4 2/20 0.50
DPP8 Q6V1X1 1/20 0.50
DPP9 Q86TI2 1/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPK1 P28482 1/20 0.47
CCR2 P41597 2/20 0.46
MAPK8 P45983 1/20 0.45
MAPK10 P53779 1/20 0.45
EPHX2 P34913 2/20 0.45
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MGLL Q99685 1/20 0.43
PARP1 P09874 1/20 0.43
KCNH2 Q12809 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794738 0.91 HDAC8 (0.63) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL4909543 0.87 HDAC8 (1.00) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL17549802 0.87 HDAC8 (1.00) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL19887507 0.87 HDAC8 (1.00) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL4905417 0.82 HDAC8 (0.80) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL4905399 0.82 HDAC8 (0.80) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL4777046 0.82 HDAC8 (0.60) HDAC8MDM2DPP4DPP7DPP8
SCHEMBL4779245 0.82 SIGMAR1 (0.55) HDAC8DPP4DPP7DPP8DPP9
SCHEMBL4779237 0.82 FAAH (0.54) HDAC8DPP4DPP7DPP8DPP9
SCHEMBL4770799 0.81 HDAC8 (0.63) HDAC8DPP4DPP7DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 HDAC8 16/4885MDM2 3744/4885DPP4 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.